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Last month at the ISSCR’s 9th Annual Meeting, Cell Stem Cell partnered with the
society and Toronto’s University Health Network to present a special premeeting
Focus session honoring one of our field’s pioneers: Ernest ‘‘Bun’’ McCulloch,
who died earlier this year (see 8:250). With his longtime collaborator, James
Till, McCulloch is widely credited for experimentally establishing the existence
of a hematopoietic stem cell. At this special tribute event, direct and indirect
scientific ‘‘descendants’’ of the famed Till and McCulloch partnership discussed
how Bun’s canny scientific insight and his careful yet imaginative interpretation
of experimental results influenced their approach to research. The diversity of
presentations highlighted the breadth of stem cell science that McCulloch
inspired, beyond hematopoiesis and leukemia, to the nervous system, and
back to pluripotent stem cells. We are very grateful to the five presenters, Norman Iscove, Guy Sauvageau, Valerie Wallace, Mick
Bhatia, and Bing Lim, as well to the comoderators James Till and Christopher Paige, for volunteering their time to participate in
this event. We also send thanks to our many advisors who helped turn the idea of this session into a reality, to those who spread
the word to ISSCR attendees, and to everyone who attended to help us honor a pioneering scientific mentor and his legacy.
Connecting Pluripotency and Cancer
c-Myc rose to prominence in the pluripotency field through being one of the original Yamanaka reprogramming factors. Although it is
now clear that exogenous c-Myc is not strictly required for reprogramming, Myc family proteins remain of interest in pluripotency
through their association with the unusual cell cycle pattern seen in PSCs and their connection to cancer. In this issue, Okuda
and colleagues use loss-of-function studies to block Myc signaling in ESCs by removing its main binding partner, Max, and show
that the cells begin to differentiate, and then die, following Max ablation. This effect appears to be due to downstream activation
of Nanog expression, since ectopic Nanog can rescue Max null ESCs, as can treatment with MAP kinase inhibitors. Nanog is also
a central player in another paper in this issue, in which Ng and coauthors identify tumor-initiating hepatocellular carcinoma cells
in the CD24+ fraction of cell lines and primary patient samples. This cell population exhibits chemoresistant properties, and expres-
sion of CD24 also correlates negatively with clinical progression and disease recurrence in patients. The authors show that the func-
tional traits of these tumor-initiating cells, as measured in mouse models, are dependent on Stat3-mediated Nanog expression.
Collectively, these two studies point to Nanog as a common factor in the Myc-dependent signaling module shared by ESCs and
cancer, and might help inform the search for both clinical interventions and improved reprogramming strategies.
Thinking Outside the Box
Sometimes in order to make progress in a new field, it helps to move beyond tried-and-true approaches. Achieving commercial
success with cell therapy appears to be no exception to this paradigm, as Mahendra Rao discusses in his Forum article. Drawing
from his experience in academia and commercial ventures, Rao comments on how the pharmaceutical industry’s traditional model
is difficult to apply to regenerative medicine, and offers some advice to entrepreneurs who hope to develop commercial applications
in the cell therapy sphere. A substantial fraction of the commercial application enacted thus far has focused onMSCs, the success of
which, as Caplan and Correa discuss in their Perspective, may well be due to the trophic and immunomodulatory properties of this
population, rather than their inherent differentiation capacity. Although the most established findings about the MSC lineage come
from studies using bone marrow-derived cells, MSC-like populations have been isolated from other tissues, including white adipose.
In their paper, Kolonin, Simmons, and colleagues apply in vivo phage display techniques to identify a surface marker on fat-derived
adipose stromal cells (ASCs), and show that this cleaved decorin functions as a previously elusive receptor for the adipokine resistin.
As Gimble and colleagues outline in their Preview, extending the use of this strategy may prove fruitful in the search for markers for
other stem cell populations.Epigenetic Heterogeneity
A growing body of evidence suggests that some pluripotent cell lines, including
iPSCs, may be better suited to some differentiation routes relative to others. In
their Brief Report, Benvenisty and colleagues use a lineage-tracing approach
to show that, in addition to retaining an epigenetic memory of their origin, human
pancreatic beta cell-derived iPSCs preferentially differentiate into insulin-
expressing cells in vitro and in vivo. Bhatia and colleagues also look at epigenetic
variation in pluripotent cells, but in this case within rather than between cell pop-
ulations. They show that they can prospectively isolate subsets of cells with
distinct differentiation propensities from an individual hESC line based on cell
surface marker expression. These subfractions also exhibit distinct epigenetic
marks at specific genetic loci that correlate with their differentiation potential.
Strikingly, the authors found that examples of classically defined bivalent marks, suggestive of a ‘‘poised’’ state prior to specific
differentiation, resolve into monovalent modifications once ESCs are subdivided in this manner. These results emphasize the risks
that come from drawing global conclusions based on population-derived data sets, and, in some ways, harken back to the central
messages that McCulloch and Till raised more than 5 decades ago.Cell Stem Cell 9, July 8, 2011 ª2011 Elsevier Inc. xi
